Exact Sciences Corp. stock (US30063P1057): Abbott deal reshapes outlook for cancer diagnostics leader

After Abbott closed its acquisition of Exact Sciences in early 2026, the future of Cologuard and the broader cancer screening portfolio is now tied to a much larger healthcare group. What this means for growth, integration risks and US-focused investors.

Exact Sciences Corp., long known as a pioneer in noninvasive colorectal cancer screening with its Cologuard test, is entering a new chapter after being acquired by Abbott in a multi?billion?dollar transaction that closed in early 2026, according to Zacks as of 04/21/2026.

The acquisition brings Exact Sciences’ established screening franchise, including Cologuard and the next?generation Cologuard Plus test, under Abbott’s diagnostics umbrella and is already contributing to double?digit growth in the buyer’s oncology diagnostics business, according to Zacks as of 04/21/2026.

As of: 27.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Exact Sciences
• Sector/industry: Medical diagnostics / cancer screening
• Headquarters/country: United States
• Core markets: Colorectal and multi?cancer screening, mainly in the US
• Key revenue drivers: Cologuard and Cologuard Plus stool?based DNA tests, oncology diagnostics
• Home exchange/listing venue: Formerly Nasdaq (ticker: EXAS)
• Trading currency: US dollar (USD)

Exact Sciences Corp.: core business model

Exact Sciences Corp. built its business around the early detection of cancer, starting with colorectal cancer, a leading cause of cancer death in the United States and other developed markets, according to American Cancer Society as of 01/10/2026.

The company’s flagship Cologuard test analyzes stool samples for DNA markers associated with colorectal cancer and advanced precancerous lesions, offering an at?home, noninvasive alternative to colonoscopy that is recommended every three years for average?risk adults, according to Exact Sciences information as of 02/05/2026.

Over time, Exact Sciences expanded beyond colorectal screening into a broader oncology diagnostics portfolio, including tissue?based and blood?based tests aimed at detecting, staging and monitoring several cancer types, according to Exact Sciences as of 03/18/2026.

The business model combines test kit sales, laboratory processing and data?driven clinical decision support, with revenue largely generated when payers reimburse physicians and clinics for completed tests.

Reimbursement coverage from US public programs and commercial insurers has been central to adoption, particularly once Cologuard secured inclusion in US preventive screening guidelines and coverage for average?risk individuals aged 45 and older, according to American Cancer Society as of 11/15/2025.

Before being acquired, Exact Sciences invested heavily in sales and marketing to drive guideline?aligned screening and in R&D for new oncology tests, which weighed on profitability but supported strong top?line growth over multiple years, according to SEC filing as of 02/20/2025.

Main revenue and product drivers for Exact Sciences Corp.

The primary revenue driver for Exact Sciences has been Cologuard, which became one of the most widely used noninvasive colorectal cancer screening tests for average?risk adults in the US, supported by national awareness campaigns and primary care outreach, according to Exact Sciences newsroom as of 12/12/2025.

A key validation for the product came when updated American Cancer Society guidelines reaffirmed Cologuard and Cologuard Plus as preferred noninvasive options for adults aged 45 and older at average risk of colorectal cancer, with testing recommended every three years, according to PR Newswire as of 05/27/2026.

The ACS guideline update supports continued demand for stool?based DNA tests and confirms their role alongside colonoscopy and fecal immunochemical tests (FIT) in screening strategies, which is relevant for volume growth under Abbott’s ownership, according to PR Newswire as of 05/27/2026.

Beyond colorectal screening, Exact Sciences developed and commercialized oncology tests for breast, prostate and other cancers, often focused on helping physicians select treatments or monitor disease progression, creating additional, though smaller, revenue streams compared with Cologuard, according to Exact Sciences as of 01/30/2026.

In the first quarter of 2026, Abbott reported that its cancer diagnostics sales increased by 13% year over year, attributing growth in part to the consolidation of Exact Sciences’ portfolio, underlining the significance of these tests within the broader diagnostics platform, according to Zacks as of 04/21/2026.

Over the medium term, further revenue drivers may include expansion of guideline recommendations, increased screening rates in eligible populations, and potential international roll?outs of stool?based DNA tests where regulatory approvals and reimbursement can be secured.

Industry trends and competitive position

Exact Sciences operates in a competitive colorectal cancer screening market that includes colonoscopy, FIT and other noninvasive tests, with adoption influenced by guideline recommendations, payer coverage and patient preferences, according to American Cancer Society as of 11/15/2025.

The reaffirmation of Cologuard and Cologuard Plus in updated ACS guidelines suggests that stool?based DNA tests are likely to remain an important tool within the screening mix, potentially supporting stable or rising test volumes over time as screening rates improve from still?suboptimal levels in the US, according to PR Newswire as of 05/27/2026.

Abbott’s ownership gives Exact Sciences access to a larger global commercial infrastructure, purchasing leverage and R&D resources, which could strengthen its competitive position in diagnostics and potentially accelerate the development and deployment of next?generation cancer tests, according to Zacks as of 04/21/2026.

At the same time, integration under a large diversified healthcare group may shift strategic priorities, including capital allocation and the pace of stand?alone branding for Exact Sciences products, which is relevant for investors tracking the oncology diagnostics segment within Abbott’s broader portfolio.

Why Exact Sciences Corp. matters for US investors

For US-focused investors, Exact Sciences historically offered exposure to a high?growth niche in medical diagnostics tied to preventive care and oncology, areas that can be less cyclical than other parts of the economy because they are driven by population health needs and insurance coverage, according to SEC filing as of 02/20/2025.

With the company now folded into Abbott, direct equity exposure for US retail investors typically occurs via Abbott shares or healthcare?focused funds that hold the acquirer, rather than through the former Exact Sciences ticker, according to MarketBeat as of 04/30/2026.

Abbott’s diagnostics division, now enhanced by Exact Sciences’ screening portfolio, forms part of a diversified healthcare revenue base that also includes medical devices and nutrition, which can influence risk?return characteristics for investors who previously considered Exact Sciences as a more pure?play cancer diagnostics stock, according to Zacks as of 04/21/2026.

For investors in the US and internationally, the case of Exact Sciences illustrates how innovative mid?cap health?care companies can eventually become part of larger diversified groups, potentially altering the investment thesis while maintaining the underlying medical and commercial relevance of their products.

Conclusion

Exact Sciences Corp. evolved from a single?product colorectal cancer screening specialist into a broader oncology diagnostics player, and its acquisition by Abbott in early 2026 has shifted the investment lens from a stand?alone growth story to a component of a diversified healthcare group, according to Zacks as of 04/21/2026.

The reaffirmation of Cologuard and Cologuard Plus as preferred noninvasive colorectal cancer screening options in updated American Cancer Society guidelines underscores the continued clinical relevance of the technology and its potential to contribute to Abbott’s diagnostics growth, according to PR Newswire as of 05/27/2026.

At the same time, integration dynamics, evolving reimbursement frameworks and competition across colorectal and broader cancer screening modalities remain important factors for investors monitoring how this asset performs within Abbott’s portfolio over the coming years.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.